(19) Japan Patent Office (JP)
`
`(12) Laid-open Patent Application Gazette (A)
`
`(51) Int. Cl.*
`A61K 35/60
`
`ID Code
`ACB
`
`(11) Laid-open Application No. S63-23819
`(43) Date of Laid-open Publication: Feb. 1, 1988
`Internal Control No.
`8615-4C
`
`(74) Agent: Mitsuyuki ARIGA, Patent Agent, and two others
`
`Examination: Not Requested Yet No. of Claims: | (Total 4 pages)
`
`(54) Title of Invention: Platelet Aggregation Inhibitor
`(21) Application No.: S61-167540
`(22) Application Date: July 16, 1986
`(72) Inventor: Shoichi MURATA,Sugamata Heights #504, 3-1-1 Imaizumi, Utsunomiya City,
`Tochigi Prefecture
`(72) Inventor: Kenji HARA, 1022-53 Nagashitsu-cho, Utsunomiya City, Tochigi Prefecture
`(71) Applicant: KAO Corporation, 1-14-10 Nihonbashi Kayaba-cho, Chuo-ku, Tokyo
`
`SPECIFICATION
`
`1.
`
`Title of Invention
`Platelet Aggregation Inhibitor
`
`2.
`
`What Is ClaimedIs:
`1.
`A platelet aggregation inhibitor containing a krill organic solvent extract as an
`active ingredient.
`2.
`The platelet aggregation inhibitor of claim 1, wherein the krill organic solvent
`extract is a phospholipid fraction.
`
`Detailed Description of the Invention
`3.
`Industrial Field of Application
`The present invention relates to a platelet aggregation inhibitor, and more specifically
`relates to a platelet aggregation inhibitor that has few side effects and high stability and thatis
`obtained by extracting it from krill using an organic solvent.
`
`Prior Art
`It is known that when a thrombus formsin a blood vessel, blood flow is greatly impaired
`and serious injury is causedto tissue. In the pathology of diseases caused by thrombus formation,
`i.e.
`thrombosis, three factors act as thrombogenic factors: the condition of the vascular wall,
`blood flow speed, and blood components; it is knownthat these interact with one another and
`play an important role. Amongthese, the role of platelets, which are one componentof blood,is
`extremely important. The possibility of inducing thrombosis through platelet rebound has been
`
`145
`
`RIMFROST EXHIBIT 1122 Page 0001
`RIMFROST EXHIBIT 1122 Page 0001
`
`

`

`experimentally and epidemiologically verified. Recently, in conjunction with clarifying the
`causative mechanism ofarteriosclerosis, it has becomeclear that stage one of the onset of
`arteriosclerosis is platelet aggregation at injured vascular endothelial cells. Therefore, in recent
`years thrombosis has been treated and prevented by the administration of drugs which are
`platelet aggregation inhibitors, such as aspirin, indomethacin, phenylbutazone, clofibrate, dextran
`sulfate, papaverine, and heparin, and polyunsaturated fatty acids such as eicosapentaenoicacid,
`either orally or by intravenousinjection.
`
`Problems the Invention Is to Solve
`Nevertheless, all of the abovementioned drugs are not completely satisfactory in some
`aspect, such asside effects, efficacy, or stability, so there is a need for the developmentof a
`platelet aggregation inhibitor with no side effects and improvedefficacy and stability to replace
`these. Also, it is necessary that this platelet aggregation inhibitor can be administered orally so
`that it can be administered daily.
`
`Meansfor Solving the Problems
`In consideration of these facts, the present inventors performed diligent research in order
`to obtain a platelet aggregation inhibitor that would satisfy the abovementioned requirements. As
`a result, they discovered that a krill organic solvent extract has a platelet aggregation inhibition
`effect, and that this substance has few side effects and improved stability, and moreover can be
`administered orally, and so completed the present invention.
`Therefore, the present invention provides a platelet aggregation inhibitor containing a
`krill organic solvent extract as an active ingredient.
`The krill used in the present invention maybe any of the Euphausia genus such as
`superba, crystallorophias, frigida, triacantha, valentini, longirostris, lucens, similis, spinifera, or
`recurva, or any of the Thysanoessa genus such as macarura, vicina, or gregaria, and is not limited
`to a particular species.
`Furthermore, the krill that is the starting material is distributed through the oceansof the
`world, and is plentiful around the South Pole in particular, where its biomass is said to range
`from hundredsof millions of tons to two billion tons. It appears to be possible to catch
`50,000,000 to 70,000,000 tons/year, which is comparable to the current annual catch offish
`worldwide, so in terms of supplying the raw material, a stable supply should be possible.
`Extraction from krill using an organic solvent is performed in the normal manner. For
`example, krill or a powder thereofis put in an organic solvent such as a non-polar solvent such
`as chloroform, benzene, butanol, or ether or a mixture of a non-polar solvent and a polar solvent
`such as chloroform-methanol, ether-ethanol, or butanol-water. Preferably,it is stirred for 2-24
`hours at 15-60°C, andfiltered. Preferred organic solvents are chloroform, chloroform-methanol,
`and butanol-water.
`The krill organic solvent extract obtained in this manner can be usedas-is as a platelet
`aggregation inhibitor, or can be concentrated or dried. But it can also be used by obtaining a
`phospholipid fraction from this extract. Typical methods of obtaining a phospholipid fraction are
`to condense the abovementioned extract, and then drip a small amount gradually into a large
`amount of cold acetone, and thereby cause a phospholipid fraction to precipitate, for example, or
`to separate and collect it by thin-layer chromatography.
`The platelet aggregation inhibitor of the present invention is manufactured by combining
`the krill organic solvent extract obtained as described aboveor a phospholipid fraction obtained
`
`146
`
`RIMFROST EXHIBIT 1122 Page 0002
`RIMFROST EXHIBIT 1122 Page 0002
`
`

`

`therefrom with a known pharmaceutical carrier as required. Furthermore, when usingthe krill
`organic solvent extract, the organic solvent in the extract is preferably removed by replacement
`with water.
`The platelet aggregation inhibitor of the present invention obtained in this manneris
`preferably administered orally in the amount of 1-20 g/day in terms of the amountof lipids in the
`extract or phospholipid fraction, for adult males, but it is possible to further increase the dose
`according to the degree of symptoms.
`Furthermore, the extract or phospholipid fraction that is the active ingredient in the
`platelet aggregation inhibitor of the present invention has extremely high safety, as indicated by
`the fact that LDso (oral) in rats of the phospholipids containedin these is 25 g/kg.
`
`Operation
`The mechanism ofthe platelet aggregation inhibition effect of the krill organic solvent
`extract of the present invention has not been explicated in detail, but it appears to derive from the
`phospholipids having large amounts of polyunsaturated fatty acids such as eicosapentaenoic acid
`that are contained in the krill organic solvent extract.
`
`Effect of the Invention
`Asdescribed above, the krill organic solvent extract of the present invention and in
`particular a phospholipid fraction derived from this exhibit an excellent platelet aggregation
`inhibition effect in oral administration, and have no toxicity or side effects, and so are an
`extremely superior platelet aggregation inhibitor.
`
`Embodiments
`The present invention is described more specifically in the following embodiments.
`
`Embodiment1
`Freeze-dried krill (Euphausia superba) was finely pulverized, 500g of this pulverized
`material was added to a butanol-water (65:35) mixture, 1000 ml, and while stirring at 50°C for
`20 hours, the lipids were extracted, and a butanol-water extraction solution was obtained by
`filtering.
`The filtered butanol-water extraction solution was concentrated under reduced pressure
`and the butanol was removed, after which additional concentration was performed to produce
`AOg of the butanol-water extraction solution (water content 28g).
`
`Embodiment 2
`(1)
`Freeze-dried krill (Euphausia superba) was finely pulverized, 500g of this pulverized
`material was added to 1000 ml of chloroform, and while stirring at 40°C for 20 hours, the lipids
`were extracted, and a chloroform extraction solution was obtainedbyfiltering.
`I)=‘The filtered chloroform extraction solution was concentrated under reduced pressure and
`solidified, and then 50 ml of a water-ethanol (1:1) solution was added, and the dried material was
`dissolved. This was again concentrated under reduced pressure and the ethanol was removed,
`producing 37g of the krill chloroform extraction solution (water content 25g).
`
`Embodiment 3
`
`147
`
`RIMFROST EXHIBIT 1122 Page 0003
`RIMFROST EXHIBIT 1122 Page 0003
`
`

`

`A chloroform extraction solution prepared in the same manner as in Embodiment 2(1)
`was concentrated under reduced pressure to about 10 ml, and then added dropwise to 2000 ml of
`acetone with stirring, and a phospholipid fraction was precipitated. The precipitate wasfiltered
`and collected under reduced pressure, and then dissolved in 30 ml of a water-ethanol 1:1 mixed
`solution, and the ethanol was removed by reduced-pressure concentration. 20g of a phospholipid
`fraction of the krill chloroform extraction solution was produced (water content 15g).
`
`Embodiment 4
`Tests were performed onthe platelet aggregation inhibition effect of the krill extracts and
`the phospholipid fractions thereof obtained in Embodiment 1, Embodiment 2, and Embodiment
`3. Specifically, krill extracts and phospholipid fractions were administered daily for two weeks
`to male Wistar rats (body weight 200g), 10 rats per group, 0.5 ml per dose, into the stomach
`using a probe. Onthe final day of the experiment, under Nembutal anesthesia, blood was
`collected from the lower abdominalartery, with a 3.8% sodium citrate solution added in the
`amount1/10. The collected blood was centrifuged at 500g, 22°C, for 6 hours to make the
`supernatant a PRP (Platelet Rich Plasma). The remaining blood was centrifuged at 1000g, 22°C,
`for 15 hours to make the supernatant a Platelet Poor Plasma (PPP). Platelet aggregation activity
`was measured using an ERMA Aggretec TE-500, and shown as maximum aggregation ratio and
`maximum aggregation time. Furthermore, platelet aggregation activity was studied with the PRP
`diluted with PPP so that the numberofplatelets became 5-7 x 10’ per 200 ul, and 20 wl of a
`saline solution with ADP 20 pmol was addedas the aggregation initiating substance. Also, rats
`administered only water were used as the control group. The results are shown in Table 1.
`
`
`Table 1
`Administration group
`Maximum aggregation ratio
`Maximum aggregation time
`
`(%)
`(min)
`59.8
`3.16
`Krill butanol-water extract
`
`Krill chloroform extract
`60.3
`3.14
`
`
`KrillWaofraction
`52.8
`2.89
`Water
`
`As shownbytheseresults, it is clear that the phospholipid fractions in the krill organic
`solvent extracts, etc. have a platelet aggregation inhibition effect.
`
`Formulation Example
`Composition:
`100 mg
`Krill phospholipid*
`®
`100 mg
`Lactose
`@
`50 mg
`Aluminum silicate
`@
`5 mg
`Magnesium stearate
`®
`* Powder with extraction solvent completely removed (Embodiment2)
`Manufacturing Method:
`Mix ©-@, andpress into tablets.
`
`The End
`
`148
`
`RIMFROST EXHIBIT 1122 Page 0004
`RIMFROST EXHIBIT 1122 Page 0004
`
`

`

`@® A A BS et CIP)
`
`@ 2D A at BD RM CA)
`
`© % i a BE
`RAGS ~— 23819
`
`@Int.Ci,*
`A 61K 35/60
`
`MCS
`ACB
`
`86AES
`8615—4C
`
`Qed MANEHE( 1988) 21 A
`
`@aink AGAR FSEAMRM 1
`
`(44 A)
`
`SRHOZH mR
`
`ER Aa61—167540
`eee
`
`@or4=BE 696101986) 7 16
`
`= — GABRFREHSRIMINL BRr0.1 75045
`FA
`HH
`Cx Wa
`
`Os YS fe HEARSESrh2k SBT1022—~ 53
`Gn FA ff ERA & Ht
`RRRPRER AMER 1 TB i4e105
`Qt BA FHt #R == #24
`
`a5
`
`ia
`
`(LEO RH
`
`BHO LH
`
`an “Is 4 SE He HD Hl
`
`HER FOR OD WO
`
`HEACM ARB RAN SDE HH mE ¢
`
`ean, MRC RA tReet erA oTAE
`
`PM bRWCYAe COMBSBRMIK LAR EB,
`
`AT [(OBMBMMH Dew MMA EL
`
`Tebpo, mRECRBeBKe on tt, me
`
`CHATA 1 & RK MM Alo
`
`BMRA FEL LCMP ROH RK. RARE ROE
`
`+27 2D ABBR Hd | > eR
`
`MRRP OE TOA Fe Bron, cHeea
`
`CEASHARORHR 1 AMR mM he
`
`AVC ERPL SN BEB*A BH tCRLTIM SS
`
`6 Ao
`
`HAO Me BOA
`
`CH LOH BS FF)
`
`EWM SH T4245 OD 656, aM O1
`
`PUB A MRO HR SUL RRB eS Dy,
`
`mepRoOB Mee rb mee OB HO FT he
`
`ARAL HR ARMA CRL. RICH
`
`feeae, BA RSM CHAAR Th Se
`
`Mittha+ TT
`i ¢ PRBAl CMH Toro eEK
`LOB ON AMADA? CER ORM
`
`SOW BA, HMR BE ORE A Ae aD
`
`MeHR ic fein, UDR TR fe fe © 8 GE OR — ee Pe Ot ER
`
`RRR MH RMS oo
`
`SoPAKRMAM~ Om> RaARt—hS 4 E Hi
`
`—1t45-—
`
`RIMFROST EXHIBIT 1122 Page 0005
`RIMFROST EXHIBIT 1122 Page 0005
`
`

`

`79988 6G-23819 (2)
`
`Woe tkOTCK Ho totes tee OR
`
`RMD AMMO SCA ZED THATS
`
`M+ FORD, Hm MHRA TSA STA
`
`BAER CKM ey
`
`ew yw,
`
`{ev F srw er, Ferra ey ey,
`
`CHAE eRPSABOFR)
`
`Pert AAw—-—-php,y FHA Lh PY HAP RE —
`
`LOL GERM, KH H OME
`
`Ry,
`
`28 Raw yw,
`
`~ RW of ED OR RY
`
`maW
`
`Bt MATA meh MM MARE AN CH
`
`wotfag¢eer Foy MBO BE LH fa 40 few
`
`BUREe-eLeoOrA MB, tT LOBE
`
`BO, BOM SL CRRPREN I LoRS Ot
`
`AR A Woh we mh ME et
`
`bBoeAbDHTHM AG
`
`BOERULOCOMMHAMSD*A (, RE
`
`CHRPRRL CA ETS HM BA
`
`Heh, Lateowe tA ACE eA
`
`LaALAM GS, FRR AO 6 BIER.
`
`Li BRAG HEL Ro
`
`2%. EEE On TAADAK SEK TT HIT
`
`LAH PUCRABMt #7 i OF BEA HH
`
`MBeELB64EOTHEO, ZNEMRA. Mt
`
`Meee m Ree LTH ATA Mh RRRM
`
`Amaia s. WM. REL OR CLERhA MS
`
`tl £RPRT SEO TH So
`
`RED M AOR RO ReEM Ch Ao ER,
`
`AAACMA PSs eT elt, WA
`
`RRO HSA pe TS AHH. SK Oh
`
`WE. Av? — 28 ( superba}, FV RA we OF 4
`
`7 *® Cerystallo rophiaajJ, 7 9 w # C( frigidad,
`
`Ot, AAKHOH C+ Be HM OAT HE TS
`
`ru T AY + (Ctriacantha},
`
`“7% +» Ff =
`
`Be
`
`CVellantini),
`
`® —#72 «b> YU AC lougirostris),
`
`COAST LORBBAM KR 8 SHE
`
`won yey AC lucens}),
`
`»*
`
`2
`
`UY * C similis ),
`
`Crhercebnseo MAM AT TRL S
`
`Rea 7s F (C spinifere), * # wt Creeurva )
`
`weteomye wer co kee, tee,
`
`Sor da zyoy 7 CEuphausiad B. 7 Hw
`
`Ama, D-H FABOAMRE BA Re 2
`
`— > (macarura), E »¥ + (CVieina}, Fe FY
`
`Bae he ARYL OHA, EHF He ERS
`
`TY (gregaria) #oOrt / cr & +t (Thysancessa )
`
`awl Pes we
`
`-~- KR FOR RE BAL RE
`
`RBSon Tne st RAS HET S OT, alse
`
`AORRSORMB MPI MAL. Rees
`
`RMMKCReE A NEM
`
`ze, AB TH ACOAYT TL LEKAROD
`
`ti5b~6 0 CT2~24 BM RHL. Fw
`
`tTSZreece bok pn bo ABE AO 5
`
`BCH, PCR M AMS <S. BEE
`
`bh. eR tLe oee- tH, Ferree
`
`mmm he ~ 2 OM P KEM HHS OL HK
`
`ahve m= A #4 mw REP RS
`
`ZORA RB hme B5000~7000
`
`KA Bri bn So
`
`HRheer/P#ORMM LT Rét SR ON TH SS
`
`CMH ry saeUTUtCH onze ae #7 1 OF we
`
`—~146—-
`
`RIMFROST EXHIBIT 1122 Page 0006
`RIMFROST EXHIBIT 1122 Page 0006
`
`

`

`39f8963-23819 (3)
`
`Ahh iw, CHetORE,L SA Ri
`
`Haw, BRKT AC EME LMS
`
`SUC MRRL Ch RE LOR
`
`MCC CH Oh re AR © om ol AK BE HD
`
`MSO K CTE SA, BCR wee ye
`
`Alek, MA BHM L,Y the wee i my
`
`HAP emowm lL, Ansa THETA Bo
`
`RAMA PO UY HMw e LL CTi~ zor Yr
`
`Vr i Rae tem oapraARme Ltn. AA
`
`R@EMORBATSCLOAR Ee Ln, TR
`
`rit aH wet Be LARK. KE OST eb
`
`SOMMER LOCH Hee SH EP Tre
`
`~PC+sS POM PCC +R aA tee
`
`a. He TH Sa
`
`SU SHERRY Me oe bh wa 74 KBR
`
`BE, HRB ml we BB A OW MH
`
`Los RE - RRP ZHRA PRA H}’ o
`
`RHR etcSsMAWAY Vr We Roi pit,
`
`cAsS
`
`AB WORh RAR DH We, RED is
`
`MRetrRrRau +R HOF vy ews LOD
`
`Lt @#bRnRkA ee TL ORR BA wR
`
`CMO)A AS ¢ Ci THEE TE DS DMA!
`
`che SH Fhe) RMDP eRe
`
`LYM RHSTCHSH ORM 4 OTH Ad
`
`CHA OR BRR HR LMA TFSA er eEM LH w
`
`C fA 3
`
`BENS BE, AT 2 OD BR A he Hh
`
`SBA OA eT 2 BB ee RH Om ob
`
`cBH 6466, RH MPO” Re Alek & it
`
`RMD oH AO RPE MICH Th
`
`REwnigiat + 7 1 PRB AHH we eAenSs
`
`© ®7t~ st
`
`( Euphausia superba ) ) © Mm ¢
`
`Sf ayy see ROBE TS ta ee Re
`
`2, COOMMsoOOFrK Fe RY Kw eK
`
`EER AT SU MRR TEED ES
`
`(65°35) BMRlC0OOm rma, So0tce
`
`Aonad
`
`CBR Om HK
`
`2ZORM. MEE ea ool Re atl,
`
`BUT SOEK EDP RY — he - KM Ree
`
`Mbroms, BRM OA ST PO BS A
`
`fio
`
`HmROEU,
`
`BP Ch Ab BH NSO) YR
`
`FR LAr ee HA - RHR ERE A
`
`PMH OBPAK CH AA Oe)Re
`
`L, *# + ~-wHw eK, 2M MMLC
`
`rel, Loh Bt: Rt Ee OT HY
`
`#7—™ - 7 tH wm 40% ( Ke 2 BP)
`
`TCKHH A M+ RRR HAL THO
`
`C ieJ
`
`#4 feo
`
`2 ii Al 2.
`
`LF CRRA Ce TCR BAe RRR
`
`AM@wmidvAA ae Fs Ti laa ryr rey
`
`Cat So
`
`# me vl 1.
`
`+ Ave — 42 ( Euphausia Superba }
`
`) & Abd. ¢
`
`2, 2OBMM500F (C1 000m OF oe
`
`Me eea naa eT i Cae a rT eS TF
`
`AH EMA, 40 7 C2 O BH, weMaAet aA
`
`—147—
`
`RIMFROST EXHIBIT 1122 Page 0007
`RIMFROST EXHIBIT 1122 Page 0007
`
`

`

`39608 63-23819 (4)
`
`oie Hemal, FAP SeT ee rb ee
`
`foe r bre vy en eRe FLA ATT IO
`
`pokes THM eH eo
`
`gpounh~a. ih wo) » fe Mo 2 0 F
`
`() FRLAF ceo kA aH HR ERE RL.
`
`Ck i158 # )HB oH fo
`
`BALAK. K- te 4-H CL IL) BRE
`5
`O mR ML. Che Mets Ee, BER
`FM se Fe ~rkREL, a> T ay 7a
`
`WG il 4.
`
`RRALARA ARO 23 Cea Rae
`
`Tinh wMekoeotol,r We aA cont,
`
`ohuwa hw mw3 77 (KBB 25 eH
`
`tEHOOMh REMMA ATR RL eo Tt
`
`who
`
`4 Al 3.
`
`Rob. 1HRLOROv4 AR -— MHF YF
`
`CHR 2007) CY ee EMH AY T F Th
`
`gM2.0) + RCL LA 2 8
`
`Mhvy PRP etEN PHOS me TS 2
`
`~AomHMEM 1 Oe ee Se CRE BR GL
`
`HM BARAHRSE Lao RR RMA AY
`
`eB, 2OCOmOT eh Ye Orn RHE +4
`
`e-PRO 8B Oe TY
`
`om Fl.
`
`0 + ROP taRI ees A
`
`meh Go WELL ORME IL eo
`
`BMemMEPB LRM eH. K- FAY KH
`
`MLE mM Met 5007, 220 C6i eeL
`
`ML LIiOBRAaR H2 0 we KB wl. RE
`
`ct Eee PRPC Platelet Rich plasma)
`
`& Leo
`
`Boomer 10007, 220715 7Hh 2
`
`BeEOGRD> Ot 7 2 HMB we hw fe Fe
`
`to baw &e 2 meh ooo MC Platelet Poor
`
`CEO) YY RAHA Roh RAR HAE
`
`plasma. PPP) & Lo Meh RRM @
`
`ATS CERAM ER OK
`
`#eT Fur Y F TE-5 O00 eAet Wee.
`
`RKABRRURKRRSM CHL AD FE,
`
`A) Fl
`
`a AES
`
`fob A BE HEL eh HR AS PRP 20088 P 5
`
`OrareTs tyr Ree
`
`10 0x9
`
`
`
`@ A b|100%
`~TXLOMEAA LSC PPPCHRL, R
`
`RR wR Ee LT ADP 2 0
`
`smol HBR GK
`
`@QOrt@erri=avra
`
`5 0 #9
`
`B20 46% Rml Ro
`
`tre. WHEL cH
`
`@DAPTIY RTT RYO SD
`
`5 mg
`
`KOA HWS LAS YP bheEH eho CORRE
`
`* SERCHA REL OH (a2. D
`
`“M1 RiCRTs
`
`es
`
`1
`
`cd
`
`Met
`
`O@O~@tBelhs FTetao
`
`Se ESE|ke Se hi]
`Be
`5
`cg
`®)
`Ch
`
`
`
`
`wey iggy ow - Km
`
`ATi germans fh we
`
` ae FT
`
`Yo» Hee il 4}
`FT
`2.89
`
`7K
`—148—
`
`3.16
`3.14
`
`RIMFROST EXHIBIT 1122 Page 0008
`RIMFROST EXHIBIT 1122 Page 0008
`
`